These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 11118065

  • 1. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.
    Jin BS, Ryu JR, Ahn K, Yu YG.
    AIDS Res Hum Retroviruses; 2000 Nov 20; 16(17):1797-804. PubMed ID: 11118065
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
    Pritsker M, Rucker J, Hoffman TL, Doms RW, Shai Y.
    Biochemistry; 1999 Aug 31; 38(35):11359-71. PubMed ID: 10471286
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E, Hummer G, Bewley CA, Clore GM.
    J Med Chem; 2005 Apr 21; 48(8):3036-44. PubMed ID: 15828842
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides.
    Shu W, Liu J, Ji H, Radigen L, Jiang S, Lu M.
    Biochemistry; 2000 Feb 22; 39(7):1634-42. PubMed ID: 10677212
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R.
    J Mol Biol; 2004 Jun 25; 340(1):9-14. PubMed ID: 15184018
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41.
    Bewley CA, Louis JM, Ghirlando R, Clore GM.
    J Biol Chem; 2002 Apr 19; 277(16):14238-45. PubMed ID: 11859089
    [Abstract] [Full Text] [Related]

  • 19. Protein design of an HIV-1 entry inhibitor.
    Root MJ, Kay MS, Kim PS.
    Science; 2001 Feb 02; 291(5505):884-8. PubMed ID: 11229405
    [Abstract] [Full Text] [Related]

  • 20. Two interaction modes of the gp41-derived peptides with gp41 and their correlation with antimembrane fusion activity.
    Ryu JR, Jin BS, Suh MJ, Yoo YS, Yoon SH, Woo ER, Yu YG.
    Biochem Biophys Res Commun; 1999 Nov 30; 265(3):625-9. PubMed ID: 10600471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.